Palvella Therapeutics’ drug candidate QTORIN rapamycin receives US patent
Palvella Therapeutics Inc, a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious and rare genetic skin diseases for which there are no US Food and Drug Administration ( …